Intercell AG
Notice
The data below are a snapshot taken at the time of the initial public offering and are not
updated regularly. For current information on a company, please go to
Investors/Listed companies.
| ISIN: | AT0000612601 | ||||||||||||
| Symbol: | ICLL | ||||||||||||
| Trading segment: | Official Market | ||||||||||||
| Market segment: | prime market | ||||||||||||
| First day of trading: | February 28, 2005 | ||||||||||||
| Offered shares: | up to 8,500,000 common stocks and up to 1,275,000 common stocks (Greenshoe) | ||||||||||||
| Category: | non-par-value bearer shares | ||||||||||||
| Number of shares (before IPO): | 24,078,000 | ||||||||||||
| Share capital (before IPO): | EUR 24,078,000 | ||||||||||||
| Offering period: | from February 14, 2005 until February 25, 2005 | ||||||||||||
| Price fixing: | The offering price was fixed and announced on February 25, 2005. | ||||||||||||
| Offer price: | EUR 5.50 | ||||||||||||
| Issuing volume: | EUR 46,750,000,-- (excl. Greenshoe) | ||||||||||||
| Underwriting group: | Goldman Sachs International, Lehman Brothers, Bank Vontobel, DZ BANK, Erste Bank der oesterreichischen Sparkassen | ||||||||||||
| Management Board: | Dr. Alexander von Gabain, CEO
Dr. Werner Lanthaler, CFO Dr. Gerd Zettlmeissl, COO Dr. Michael Joachim Buschle, CTO |
||||||||||||
| Supervisory Board: | Dr. Ernst Afting, Vorsitzender
Michel Gréco, stellvertretender Vorsitzender Dr. Hans Albert Küpper Dr. Helmut Schühsler Cathrin Petty Dr. David Ebsworth Dr. Luke Evnin Dr. Emilio Emini James Sulat |
||||||||||||
| Shareholder structure (before IPO not including own shares): |
|
||||||||||||
| Address: | Intercell AG
Campus Biocenter 2 A-1030 Vienna Phone: + 43 1 20620-0 |
||||||||||||
| Internet: | http://www.intercell.com/ | ||||||||||||
| Company profile: |
Intercell is a fast-growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prophylactic and therapeutic treatment of diseases with substantial unmet needs. Since becoming operational in 1998, Intercell's mission is the discovery and development of innovative immunological products and technologies. Today, Intercell is one of the world's most promising young biotech companies. The company's unique proposition is based on the combination of antigens and Immunizers (adjuvants) proprietary technology platforms, as well as in-house GMP facilities. Intercell's technology has been endorsed by collaborative agreements with global pharmaceutical companies including Aventis, Merck&Co, Inc. and the Statens Serum Institute. Intercell has a broad development pipeline with a vaccine for Japanese Encephalitis, a vaccine for Hepatitis C undergoing phase II trials, and five products focused on infectious diseases in the pre-clinical phase, including a Pneumonia vaccine, a Group A Streptococcus vaccine and a traveler's diarrhea vaccine. |
